Harvard Bioscience, Inc is a medical instruments & supplies business based in the US. Harvard Bioscience shares (HBIO) are listed on the NASDAQ and all prices are listed in US Dollars. Harvard Bioscience employs 428 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Harvard Bioscience
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – HBIO – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- HBIO shares summary
- Compare share dealing platforms
- Is HBIO stock a buy or sell?
- Stock performance over time
- Can I short HBIO shares?
- Are HBIO shares over-valued?
- Harvard Bioscience's financials
- How volatile are HBIO shares?
- Does Harvard Bioscience pay a dividend?
- Have HBIO shares ever split?
- Other common questions
Harvard Bioscience stock price (NASDAQ: HBIO)Use our graph to track the performance of HBIO stocks over time.
Harvard Bioscience shares at a glance
|Latest market close||$7.00|
|52-week range||$2.74 - $8.55|
|50-day moving average||$7.68|
|200-day moving average||$6.18|
|Wall St. target price||$9.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.12|
Buy Harvard Bioscience shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Harvard Bioscience stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Harvard Bioscience price performance over time
|1 week (2021-07-18)||N/A|
|1 month (2021-06-29)||-16.67%|
|3 months (2021-04-29)||-2.78%|
|6 months (2021-01-25)||N/A|
|1 year (2020-07-25)||N/A|
|2 years (2019-07-25)||N/A|
|3 years (2018-07-25)||N/A|
|5 years (2016-07-25)||N/A|
Is Harvard Bioscience under- or over-valued?
Valuing Harvard Bioscience stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Harvard Bioscience's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Harvard Bioscience's PEG ratio
Harvard Bioscience's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.89. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Harvard Bioscience's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Harvard Bioscience's EBITDA
Harvard Bioscience's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $10.5 million.
The EBITDA is a measure of a Harvard Bioscience's overall financial performance and is widely used to measure a its profitability.
Harvard Bioscience financials
|Revenue TTM||$105.3 million|
|Operating margin TTM||2.76%|
|Gross profit TTM||$58 million|
|Return on assets TTM||1.18%|
|Return on equity TTM||-5.18%|
|Market capitalisation||$321.7 million|
TTM: trailing 12 months
Shorting Harvard Bioscience shares
There are currently 665,745 Harvard Bioscience shares held short by investors – that's known as Harvard Bioscience's "short interest". This figure is 3.2% down from 687,997 last month.
There are a few different ways that this level of interest in shorting Harvard Bioscience shares can be evaluated.
Harvard Bioscience's "short interest ratio" (SIR)
Harvard Bioscience's "short interest ratio" (SIR) is the quantity of Harvard Bioscience shares currently shorted divided by the average quantity of Harvard Bioscience shares traded daily (recently around 291993.42105263). Harvard Bioscience's SIR currently stands at 2.28. In other words for every 100,000 Harvard Bioscience shares traded daily on the market, roughly 2280 shares are currently held short.
However Harvard Bioscience's short interest can also be evaluated against the total number of Harvard Bioscience shares, or, against the total number of tradable Harvard Bioscience shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Harvard Bioscience's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Harvard Bioscience shares in existence, roughly 20 shares are currently held short) or 0.0187% of the tradable shares (for every 100,000 tradable Harvard Bioscience shares, roughly 19 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Harvard Bioscience.
Find out more about how you can short Harvard Bioscience stock.
Harvard Bioscience share dividends
We're not expecting Harvard Bioscience to pay a dividend over the next 12 months.
Have Harvard Bioscience's shares ever split?
Harvard Bioscience's shares were split on a 1319:1000 basis on 3 November 2013. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1319 shares. This wouldn't directly have changed the overall worth of your Harvard Bioscience shares – just the quantity. However, indirectly, the new 24.2% lower share price could have impacted the market appetite for Harvard Bioscience shares which in turn could have impacted Harvard Bioscience's share price.
Harvard Bioscience share price volatility
Over the last 12 months, Harvard Bioscience's shares have ranged in value from as little as $2.74 up to $8.55. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Harvard Bioscience's is 1.7606. This would suggest that Harvard Bioscience's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Harvard Bioscience overview
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development. It offers physiology, cell, and molecular instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. The company also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products, systems, services, and solutions with a focus on physiologic monitoring solutions. It markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. The company primarily sells its products under Harvard Apparatus, Biochrom, Hoefer, Panlab, Warner Instruments, Hugo Sachs Elektronik, Scie-Plas, BTX, Multi Channel Systems, HEKA, DSI, Ponemah, and Buxco brand names in North America, Europe, China, and internationally. Harvard Bioscience, Inc.
Stocks similar to Harvard Bioscience
Harvard Bioscience in the news
What Type Of Shareholders Make Up Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Share Registry?
Harvard Bioscience Schedules Second Quarter 2021 Earnings Conference Call for August 5, 2021 at 8:00 AM ET
Harvard Bioscience Schedules Second Quarter 2021 Earnings Conference Call for August 5, 2021 at 8:00 AM ET
Frequently asked questionsWhat percentage of Harvard Bioscience is owned by insiders or institutions?
Currently 11.093% of Harvard Bioscience shares are held by insiders and 74.815% by institutions. How many people work for Harvard Bioscience?
Latest data suggests 428 work at Harvard Bioscience. When does the fiscal year end for Harvard Bioscience?
Harvard Bioscience's fiscal year ends in December. Where is Harvard Bioscience based?
Harvard Bioscience's address is: 84 October Hill Road, Holliston, MA, United States, 01746 What is Harvard Bioscience's ISIN number?
Harvard Bioscience's international securities identification number is: US4169061052 What is Harvard Bioscience's CUSIP number?
Harvard Bioscience's Committee on Uniform Securities Identification Procedures number is: 416906105
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert